Diabetes and overweight associate with non‐APOE4 genotype in an alzheimer's disease population
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is a risk factor for late‐onset Alzheimer's disease (AD), and studies suggest that pathogenic effects of diabetes and insulin resistance may be associated with non‐APOE4 AD. Therefore, we examined association of the APOE4 allele with diabetes in an AD population. Retrospective and cross‐sectional clinical and APOE‐genotype data on 465 cases with probable or definite AD previously ascertained by the National Institute of Mental Health Genetics Initiative were analyzed by regression analysis. Dependent variables included presence of APOE4 alleles and AD onset age. Diabetes was the independent variable and covariates included gender, hypertension, and other potentially confounding variables. We also examined for interactions involving weight status as overweight and obesity are independent risk factors for insulin resistance, diabetes and AD. Prevalence of diabetes was 13% among AD cases without an APOE4 allele and 5–6% among AD cases with one or two APOE4 alleles. Odds ratio for diabetes was 0.26 [95% CI: 0.09–0.73; P = 0.011] by APOE4 status after adjusting for all covariates. Diabetes did not associate with AD onset age. Among other independent variables included in the model, APOE4 and diuretic medication treatment were associated with AD onset age. In a subset of cases with body mass index determinations, overweight also exhibited an inverse association with APOE4 and associated with decreased non‐APOE4 AD onset age. Pathogenic mechanisms associated with diabetes and overweight are enriched in AD cases without an APOE4 allele. © 2008 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499 · cited 1×
“In cases where brain autopsy was performed, Khachaturian criteria [Khachaturian, 1985] were used to assess pathological changes consistent with AD or other disorders.”
MethodObesity and Vascular Risk Factors at Midlife and the Risk of Dementia and Alzheimer Disease
Kivipelto, M., Ngandu, T., Fratiglioni, L., Viitanen, M., Kåreholt, I., Winblad, B., Helkala, E.-L., Tuomilehto, J., Soininen, H., & Nissinen, A. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1556 · Cited by 1,291 · cited 2×
“…epidemiological studies show that overweight is a risk factor for dementia or AD [Barrett-Connor et al., 1996; Gustafson et al., 2003; Nourhashemi et al., 2003; Buchman et al., 2005; Kivipelto et al., 2005; Rosengren et al., 2005; Stewart et al., 2005; Whitmer et al., 2005; Hayden et al., 2006].”
BackgroundDiabetes mellitus and risk of Alzheimer disease and decline in cognitive function
Arvanitakis, Z., Wilson, R. S., Bienias, J. L., Evans, D. A., & Bennett, D. A. (2004) · Archives of Neurology · doi:10.1001/archneur.61.5.661 · Cited by 1,258 · cited 2×
“Type 2 diabetes or insulin resistance has been shown to be a risk factor for late-onset Alzheimer’s disease (AD) in several epidemiological studies [Kuusisto et al., 1997; Leibson et al., 1997; Ott et al., 1999; Luchsinger et al., 2001, 2004, 2005; Peila et al., 2002; Arvanitakis et al., 2004; Xu et al., 2004; Akomola…”
BackgroundPrevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210
Type 2 Diabetes, APOE Gene, and the Risk for Dementia and Related Pathologies
Peila, R., Rodriguez, B. L., & Launer, L. J. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1256 · Cited by 1,207 · cited 1×
“RBP4 has been shown to directly alter transthyretin-mediated clearance and amyloidogenicity of beta amyloid [White and Kelly, 2001; Raghu and Sivakumar, 2004], and polymorphisms in the RBP4 gene have been associated with familial amyloid polyneuropathy [Soares et al., 2005].”
BackgroundInsulin and neurodegenerative disease: shared and specific mechanisms
Craft, S., & Stennis Watson, G. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00681-7 · Cited by 830
Risk of Dementia among Persons with Diabetes Mellitus: A Population-based Cohort Study
Leibson, C. L., Rocca, W. A., Hanson, V. A., Cha, R., Kokmen, E., O'Brien, P. C., & Palumbo, P. J. (1997) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009106 · Cited by 700 · cited 2×
“Type 2 diabetes or insulin resistance has been shown to be a risk factor for late-onset Alzheimer’s disease (AD) in several epidemiological studies [Kuusisto et al., 1997; Leibson et al., 1997; Ott et al., 1999; Luchsinger et al., 2001, 2004, 2005; Peila et al., 2002; Arvanitakis et al., 2004; Xu et al., 2004; Akomola…”
BackgroundRisner, M. E., Saunders, A. M., Altman, J. F. B., Ormandy, G. C., Craft, S., Foley, I. M., Zvartau-Hind, M. E., Hosford, D. A., Roses, A. D., & for the Rosiglitazone in Alzheimer's Disease Study Group (2006) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500369 · Cited by 686
ApoE-4 and Age at Onset of Alzheimer's Disease: The NIMH Genetics Initiative
Blacker, D., Haines, J. L., Rodes, L., Terwedow, H., Go, R. C. P., Harrell, L. E., Perry, R. T., Bassett, S. S., Chase, G., Meyers, D., et al. (1997) · Neurology · doi:10.1212/wnl.48.1.139 · Cited by 479 · cited 4×
“As additional studies are needed to clarify the interaction between APOE and diabetes or insulin resistance in AD, we examined the association of diabetes with APOE genotype in a large AD population rigorously characterized for genetic research studies [Blacker et al., 1997].”
BackgroundInfluentialStewart, R., Masaki, K., Xue, Q.-L., Peila, R., Petrovitch, H., White, L. R., & Launer, L. J. (2005) · Archives of Neurology · doi:10.1001/archneur.62.1.55 · Cited by 478
Culmsee, C., monnig, J., Kemp, B. E., & Mattson, M. P. (2001) · Journal of Molecular Neuroscience · doi:10.1385/jmn:17:1:45 · Cited by 340
Obesity‐related leptin regulates Alzheimer's Aβ
Fewlass, D. C., Noboa, K., Pi‐Sunyer, F. X., Johnston, J. M., Yan, S. D., & Tezapsidis, N. (2004) · The FASEB Journal · doi:10.1096/fj.04-2572com · Cited by 308 · cited 1×
“Leptin also may modulate beta amyloid levels [Fewlass et al., 2004].”
BackgroundVascular Risk Factors for Incident Alzheimer Disease and Vascular Dementia: The Cache County Study
Hayden, K. M., Zandi, P. P., Lyketsos, C. G., Khachaturian, A. S., Bastian, L. A., Charoonruk, G., Tschanz, J. T., Norton, M. C., Pieper, C. F., Munger, R. G., et al. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000213814.43047.86 · Cited by 293 · cited 2×
“…epidemiological studies show that overweight is a risk factor for dementia or AD [Barrett-Connor et al., 1996; Gustafson et al., 2003; Nourhashemi et al., 2003; Buchman et al., 2005; Kivipelto et al., 2005; Rosengren et al., 2005; Stewart et al., 2005; Whitmer et al., 2005; Hayden et al., 2006].”
BackgroundAdiposity indices and dementia
Gustafson, D. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70526-9 · Cited by 237
Body Mass Index, Other Cardiovascular Risk Factors, and Hospitalization for Dementia
Rosengren, A. (2005) · Archives of Internal Medicine · doi:10.1001/archinte.165.3.321 · Cited by 207 · cited 2×
“…epidemiological studies show that overweight is a risk factor for dementia or AD [Barrett-Connor et al., 1996; Gustafson et al., 2003; Nourhashemi et al., 2003; Buchman et al., 2005; Kivipelto et al., 2005; Rosengren et al., 2005; Stewart et al., 2005; Whitmer et al., 2005; Hayden et al., 2006].”
BackgroundBody mass index and incidence of dementia: The PAQUID study
Nourhashémi, F., Deschamps, V., Larrieu, S., Letenneur, L., Dartigues, J.-F., & Barberger-Gateau, P. (2003) · Neurology · doi:10.1212/01.wnl.0000038910.46217.aa · Cited by 193
Leptin: a potential cognitive enhancer?
Harvey, J., Shanley, L. J., O'Malley, D., & Irving, A. J. (2005) · Biochemical Society Transactions · doi:10.1042/bst0331029 · Cited by 162 · cited 1×
“Leptin receptors also are found in hippocampus and other brain regions affected by AD, and leptin has been shown to facilitate hippocampal synaptic plasticity and cognition [Harvey et al., 2005].”
BackgroundAntihypertensive Medication Use and Incident Alzheimer Disease: The Cache County Study
Khachaturian, A. S. (2006) · Archives of Neurology · doi:10.1001/archneur.63.5.noc60013 · Cited by 3 · cited 1×
“Previous studies have shown that diuretics reduce risk for AD and rate of decline in AD independent of blood pressure [Guo et al., 1999; Khachaturian et al., 2006].”
Result
Cited by
Meta-analysis of Alzheimer’s disease risk with obesity, diabetes, and related disorders
Profenno, L. A., Porsteinsson, A. P., & Faraone, S. V. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.013 · Cited by 718
Self-citationHow does diabetes accelerate Alzheimer disease pathology?
Sims-Robinson, C., Kim, B., Rosko, A., & Feldman, E. L. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.130 · Cited by 492
Claxton, A., Baker, L. D., Wilkinson, C. W., Trittschuh, E. H., Chapman, D., Watson, G. S., Cholerton, B., Plymate, S. R., Arbuckle, M., & Craft, S. (2013) · Journal of Alzheimer’s Disease · doi:10.3233/jad-122308 · Cited by 215
Puig, K. L., Floden, A. M., Adhikari, R., Golovko, M. Y., & Combs, C. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030378 · Cited by 152
Beyond the CNS: The many peripheral roles of APOE
Martínez-Martínez, A. B., Torres-Perez, E., Devanney, N., Del Moral, R., Johnson, L. A., & Arbones-Mainar, J. M. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.104809 · Cited by 149
Metadata
- Authors
- Profenno, L. A., & Faraone, S. V.
- Venue
- American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
- Publisher
- Wiley
- Published
- 2008-08-22
- Volume
- 147B
- Issue
- 6
- Pages
- 822-829
- ISSN
- 1552-4841 (ISSN-L)
- 1552-485X
- OpenAlex
- W2105599846
- Cited by
- 39
- References
- 18
- FWCI
- 3.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.